Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021044287 - TREATMENT OF LIVER DISEASE OR DISORDER COMPRISING ACTRII RECEPTOR ANTAGONISTS

Publication Number WO/2021/044287
Publication Date 11.03.2021
International Application No. PCT/IB2020/058114
International Filing Date 01.09.2020
IPC
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 1/16 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61P 1/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 3/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
04Anorexiants; Antiobesity agents
A61P 3/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
08for glucose homeostasis
10for hyperglycaemia, e.g. antidiabetics
C07K 16/2863
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2863against receptors for growth factors, growth regulators
C07K 2317/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
24containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Applicants
  • NOVARTIS AG [CH]/[CH]
Inventors
  • COLEMAN, Laura
  • MEYERS, C. Daniel
  • ROUBENOFF, Ronenn
  • TRIFILIEFF, Estelle
Agents
  • ROY, Madhuri
Priority Data
62/895,10703.09.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) TREATMENT OF LIVER DISEASE OR DISORDER COMPRISING ACTRII RECEPTOR ANTAGONISTS
(FR) TRAITEMENT DE MALADIE OU DE TROUBLE HÉPATIQUE COMPRENANT DES ANTAGONISTES DE RÉCEPTEUR ACTRII
Abstract
(EN)
The present disclosure provides an ActRII antagonist, e.g., the ActRIIA and/or ActRIIB antagonist, e.g., an anti-ActRII receptor antibody or antigen-binding fragment thereof, e.g., bimagrumab, for treating or preventing liver disease or disorder in a subject in need thereof. The present disclosure also relates to pharmaceutical combinations comprising such ActRII antagonists and at least one further therapeutic agent in the treatment or prevention of liver disease or disorder.
(FR)
La présente invention concerne un antagoniste ActRII, par exemple, l’antagoniste ActRIIA et/ou ActRIIB, par exemple, un anticorps anti-récepteur ActRII ou son fragment de liaison à l’antigène, par exemple, le bimagrumab, pour le traitement ou la prévention de la maladie ou du trouble hépatique chez un sujet en ayant besoin. La présente invention concerne également des combinaisons pharmaceutiques comprenant de tels antagonistes ActRII et au moins un agent thérapeutique supplémentaire dans le traitement ou la prévention de la maladie ou du trouble hépatique.
Latest bibliographic data on file with the International Bureau